Skip to content

Avanos Medical AVNS Gain Loss On Sale Of Property Plant Equipment

Gain Loss On Sale Of Property Plant Equipment at other companies

Charles River Laboratories logo
Charles River LaboratoriesCRL

Other financials

Income statement

See full
Revenue$182.2M+8.8%
Gross profit$94.2M+4.9%
Operating income$8.9M-13.6%
Net income$5.1M-22.7%
EPS (diluted)$0.11-21.4%

Balance sheet

See full
Cash & equivalents$65.6M-32.4%
Total debt$138.4M-1.8%
Total equity$782.1M-6.8%
Total assets$1.1B-5.2%

Cash flow

See full
Operating cash flow-$12.3M-148%
CapEx$4.3M-35.8%
Free cash flow-$16.6M-187%

Valuation

See full
Market cap$1.17B+108%
Enterprise value$1.24B+105%
P/S1.6×+0.8×

Profitability

See full
Gross margin50%-4.6pp
Operating margin-9.1%-4.2pp
Net margin-10.4%-4.7pp
FCF margin1.6%-14.9pp

Returns & leverage

See full
Return on equity-9.2%-3.9pp
Debt / equity0.2×0.0×
Current ratio2.5×-0.1×

Where this comes from

Reported directly by Avanos Medical in its filing.

Tagged under the XBRL concept us-gaap:GainLossOnSaleOfPropertyPlantEquipment.

The official record: Avanos Medical’s 10-K, filed February 24, 2026, on SEC EDGAR. View the filing →

Ask your AI about Avanos Medical's gain loss on sale of property plant equipment.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Avanos Medical's gain loss on sale of property plant equipment?
Avanos Medical (AVNS) reported gain loss on sale of property plant equipment of -$2.33M in Q4 2025.
How has Avanos Medical's gain loss on sale of property plant equipment changed year-over-year?
Avanos Medical's gain loss on sale of property plant equipment decreased by 675.0% year-over-year, from -$300K to -$2.33M.
What is the long-term trend for Avanos Medical's gain loss on sale of property plant equipment?
Over 3 years (2022 to 2025), Avanos Medical's gain loss on sale of property plant equipment has grown at a 103.7% compound annual growth rate (CAGR), from -$1.1M to -$9.3M.